Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Blood-Brain Barrier (BBB) Shuttle Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD98/SLC3A2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD98/SLC3A2 ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CD98/SLC3A2 Products |
| Gene Delivery | CD98/SLC3A2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View CD98/SLC3A2 Products |
| Benchmark Ab | Anti-CD98/SLC3A2 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View CD98/SLC3A2 Products |
| Validator | CD98/SLC3A2 siRNA Set For target knockdown and specificity validation. |
View CD98/SLC3A2 Products |
| Related Target A | LAT1/SLC7A5 The light-chain heterodimeric partner of CD98hc, critical for amino acid transport function. |
View LAT1 Products |
| Related Target B | Transferrin Receptor (TfR/CD71) Comparative target for receptor-mediated transcytosis (RMT) and BBB shuttle design. |
View TfR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Heterodimeric Complex | Co-expression ready constructs and high-purity HEK293-expressed monomer/complex proteins. |
| Cross-species Cyno/Mouse Evaluation | Human, Cynomolgus, and Mouse ortholog proteins strictly verified by mass spectrometry and sequence analysis. |
| Lack of Controls | Clinical benchmark antibodies (biosimilars) included for assay baseline calibration. |
| False Positives in Binding Assays | Sequence-verified siRNA included for target knockdown validation in cell-based assays. |
Live CD98/SLC3A2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD98/SLC3A2 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to antibody-drug conjugates (ADCs) and multi-specific blood-brain barrier (BBB) shuttles. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific heterodimer conformations and pH-sensitive binding kinetics to maximize therapeutic windows.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | AstraZeneca, Ignis Therapeutics | Solid Tumors, Non-Small Cell Lung Cancer (NSCLC) | Internalization Assay (Need high-purity, native-glycosylation ECD-Fc proteins) |
| BBB Shuttle (Bispecific/Multispecific) | Denali Therapeutics, JCR Pharmaceuticals | Central Nervous System (CNS) Disorders, Brain Metastases | pH-Dependent Binding Assay (Need highly stable recombinant monomeric CD98hc) |
| Monoclonal Antibody (mAb) | Academic Institutions, Biotech Startups | Hematological Malignancies, Lymphoma | Cell-based Flow Cytometry (Need Lentivirus for robust stable cell line generation) |